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Abstract
Primary amebic meningoencephalitis (PAM) caused by the free-living ameba Naegleria fowleri is 
a rare but rapidly fatal disease of the central nervous system (CNS) affecting predominantly 
young, previously healthy persons. No effective chemotherapeutic prophylaxis or treatment has 
been identified. Recently, three transplant-associated clusters of encephalitis caused by another 
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free-living ameba, Balamuthia mandrillaris, have occurred, prompting questions regarding the 
suitability of extra-CNS solid organ transplantation from donors with PAM. During 1995–2012, 
21 transplant recipients of solid organs donated by five patients with fatal cases of PAM were 
reported in the United States. None of the recipients developed PAM and several recipients tested 
negative for N. fowleri by serology. However, historical PAM case reports and animal 
experiments with N. fowleri, combined with new post-mortem findings from four PAM patients, 
suggest that extra-CNS dissemination of N. fowleri can occur and might pose a risk for disease 
transmission via transplantation. The risks of transplantation with an organ possibly harboring N. 
fowleri should be carefully weighed for each individual recipient against the potentially greater 
risk of delaying transplantation while waiting for another suitable organ. In this article we present 
a case series and review existing data to inform such risk assessments.
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Introduction
Naegleria fowleri is a free-living ameba (FLA) inhabiting warm freshwater sites. It has also 
been isolated from soil (1). N. fowleri enters the body when contaminated water moves up 
the nose, such as during swimming or nasal irrigation (2). Amebae then cross the cribriform 
plate and reach the brain through the olfactory tract to cause primary amebic 
meningoencephalitis (PAM) (1) (Table 1). PAM progresses rapidly and has a mortality of 
approximately 99%, based on documented United States (US) cases. During 1962–2012, 
128 PAM cases were reported in the US (3, CDC unpublished data); only one survived (4). 
Along with a second case from Mexico (5), these are the only well-documented survivors in 
North America through 2012.
PAM generally affects young, previously healthy individuals (3) who may be viewed as 
candidates for deceased-donor organ donation. Successful organ donations from three PAM 
patients have been reported (6–8). However, while no cases of N. fowleri transplant 
transmission have been documented thus far, the true risk is unknown. Transplant 
transmission of another FLA, Balamuthia mandrillaris, has been reported on three occasions 
(9–11), prompting questions about the potential risk for transplant transmission of N. fowleri 
and about the similarities and differences between these two amebae in terms of 
epidemiologic and clinical characteristics and diagnostic methods that might assist in 
recognizing and differentiating these cases to assist with management of recipients post-
donation (Table 1). Consequently, the Centers for Disease Control and Prevention (CDC) 
has collaborated with attending physicians and pathologists to investigate possible Naegleria 
dissemination to organs outside the central nervous system (CNS). We summarize new 
pathology and laboratory data obtained from previously unreported PAM patients and new 
serology data from transplant recipients associated with PAM organ donors. Additionally, 
we review animal studies and historical human data suggestive of possible extra-CNS 
amebic dissemination, and discuss the potential risk for N. fowleri transmission through 
solid organ transplantation.
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Materials and Methods
PAM diagnosis requires specialized laboratory testing only available in a few laboratories 
including CDC, which is consulted for diagnostic, clinical, and epidemiologic assistance by 
health professionals in the majority of reported PAM cases. The patients described herein 
represent all PAM cases during 2009–2012 for whom CDC provided laboratory testing and 
who either (1) donated organs or (2) underwent expanded autopsies with extra-CNS tissue 
testing. Clinical descriptions were compiled from reports from healthcare personnel; 
hospital, laboratory, and autopsy record reviews; and, in one patient, published literature. 
Laboratory tests performed at CDC are also summarized. Various methodologies are 
available at CDC to identify FLA, including immunohistochemical techniques, culture, and 
a triplex real-time polymerase chain reaction (PCR) test. Immunohistochemical techniques, 
such as indirect immunofluorescence (IIF) (12) and immune alkaline phosphatase (IHC) 
(13), use antibody specific for N. fowleri followed by microscopic examination to identify 
N. fowleri in tissue, culture, or cerebrospinal fluid (CSF). PCR testing can simultaneously 
identify and differentiate three meningoencephalitis-causing FLA (N. fowleri, 
Acanthamoeba spp., and Balamuthia mandrillaris) (14) and is used at CDC to diagnose and 
confirm PAM cases. An experimental immunofluorescence antibody (IFA) assay can detect 
serum antibodies to N. fowleri using an antibody competition assay. A positive serologic 
response is considered to be a titer of 1:128 or greater and indicates exposure to N. fowleri 
(4).
Results
Case #1
On August 14, 2009, a 10-year-old male was hospitalized in Florida with a 1-day history of 
meningitis-like symptoms (Table 2). He was given ceftriaxone, rifampin, and vancomycin 
for presumptive bacterial meningitis but later developed cough, shortness of breath, 
confusion, disorientation with hallucinations, and at least one grand mal seizure. A 
computed tomography (CT) brain scan without contrast on August 16 showed diffuse 
edema. Multiple organ system failure occurred and he died on August 17. Both kidneys 
were recovered and transplanted into two recipients.
On August 19, a post-mortem diagnosis of PAM was made when amebic trophozoites were 
observed in brain tissue at autopsy. CDC confirmed N. fowleri in the brain tissue by IIF; 
histopathology revealed deep parenchymal arterioles cuffed with trophozoites in the 
perivascular spaces. Autopsy specimens, including hematoxylin and eosin-stained (H&E) 
slides of pre-transplant kidney biopsies, were sent to CDC; no amebae were found in the 
kidneys. However, trophozoites were observed in H&E-stained sections of spleen, thyroid, 
lung, and heart; these tissues were also positive by IIF and IHC (Figure 1). Amebae 
observed in these organs were sparse; mostly in gaps, spaces, lumens, or along the periphery 
of tissues; frequently degraded; and generally not associated with tissue reaction, either 
inflammation or necrosis. The spleen showed fibro-congestive changes including 
polymorphonuclear leukocyte (PMN) infiltrates with numerous amebic antigens and 
degraded amebae along with a few whole amebae in the parenchyma on IIF, although only a 
few amebic particles and one whole ameba were seen on the periphery of the spleen by IHC. 
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Amebae were also observed on the edge and inside the parenchymal thyroid tissue by IIF 
and IHC. Some amebae in the lung sections were phagocytized by PMNs. Liver tissue tested 
negative for N. fowleri by IIF and IHC. All postmortem fresh tissue specimens obtained 
during autopsy were placed in cassettes and submerged in the same container of formalin 
before sectioning, potentially resulting in cross-contamination from the brain.
The kidney recipients were informed about these findings and followed closely for potential 
signs of organ rejection and PAM. One recipient had a kidney biopsy 1 year post-transplant 
per protocol, showing only mild fibrosis. The other recipient had diminished renal function 
with two biopsies to evaluate for possible rejection, at 9 months and 2.5 years post-
transplant, both of which showed moderate fibrosis. Neither of the grafted kidneys showed 
evidence of Naegleria and, in August 2012, both recipients were well. Neither were tested 
for N. fowleri exposure or given anti-amebic chemotherapy.
Case #2
On September 18, 2009, a previously described 22-year-old male PAM patient in Florida, 
diagnosed pre-mortem, donated his kidneys, lungs, liver, heart, pancreas, and bowel to seven 
recipients (8). The pancreas/bowel recipient was alive and well in September 2011 and five 
other recipients were alive and well in March 2012. The right lung recipient died in August 
2010 from recurrent disease unrelated to his transplant without evidence of PAM. None of 
the recipients received anti-amebic chemotherapy for N. fowleri exposure.
Approximately 2-years post-transplant, the liver recipient tested negative for N. fowleri 
antibodies with titers of 1:8 and lower. At this time, CDC obtained a small piece of banked 
heart tissue biopsied from the heart recipient approximately 1 month post-transplant; it 
tested negative for amebae by culture and Giemsa staining. Since then, multiple protocol 
biopsies of the heart have shown no evidence of rejection or other pathology and the heart 
recipient was alive and well in June 2012.
Case #3
On August 9, 2011, a 16-year-old female in Florida presented to an emergency room with a 
3-day history of headache, fever, and vomiting. Electrolytes and blood counts were normal. 
She was treated with an intravenous (IV) fluid bolus and ceftriaxone, and discharged. On 
August 10, she was hospitalized with high fever, neck pain and stiffness, fatigue, and altered 
mental status. PAM was presumptively diagnosed because of motile amebae observed in her 
CSF and later confirmed by PCR and culture. PAM treatment was initiated with IV 
amphotericin B, azithromycin, fluconazole, and oral rifampin with dexamethasone for 
anticipated cerebral edema. Subsequently, she developed unequal pupils and progressive 
lethargy. On August 11, she was intubated and given hypertonic saline and mannitol. 
Intrathecal amphotericin B was administered through a lumbar spinal needle and a second 
CSF sample demonstrated the continued presence of motile amebae and progressive 
pleocytosis. On August 12, an external ventricular drain was placed and showed normal 
intracranial pressure. Intraventricular amphotericin B and IV chlorpromazine were 
administered. She deteriorated and died on August 13.
Roy et al. Page 4
Am J Transplant. Author manuscript; available in PMC 2015 December 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
On August 14, her kidneys, lungs, liver, and pancreas were recovered and transplanted into 
four recipients. All recipients were alive and well in March 2012. One recipient with a 
bilateral lung transplant received treatment for possible Naegleria exposure with 2 days of 
IV Ambisome (August 14–16, 2011), which was stopped because of renal dysfunction; no 
further anti-amebic treatment was given. Approximately 7 weeks post-transplant, the four 
recipients provided serum for serologic testing of N. fowleri antibodies at CDC. All four 
tested negative with titers of 1:8 or lower.
Case #4
On August 19, 2011, a 14-year-old male in Kansas presented to hospital 1 day after illness 
onset. He was presumptively treated for meningitis with ceftriaxone, vancomycin, acyclovir, 
and mannitol. An MRI of the brain on August 20 was unremarkable. His symptoms 
progressed and he developed increased confusion, agitation, tonic-clonic activity, and had a 
seizure. He subsequently desaturated and was intubated. Tonsilar herniation of the brain 
occurred and he was pronounced dead on August 24. He was not an organ donor.
Post-mortem CSF tested positive for N. fowleri by PCR at CDC. CDC also received slides of 
brain, spinal cord, kidney, lung, liver, and heart from an expanded autopsy. Only CNS 
tissues tested positive for N. fowleri by IHC whereas CNS, kidney, and lung tissues tested 
positive by IIF, with many trophozoites and much antigenic debris observed in the kidney, 
and a few trophozoites with a little debris observed in both lungs. Six slides of kidney, lung, 
and liver tissues taken from patients with diseases other than PAM were also sent to CDC as 
controls—all tested negative by IIF. As with Case #1, cross-tissue contamination possibly 
occurred because all organs were sectioned using the same tools (rinsed between organs) 
and cassettes containing all organ specimens were placed in the same formalin-filled 
container prior to processing. However, in Case #4, the liver and heart, which were negative 
for N. fowleri by IHC and IIF, were also in this same container and placed in the same 
cassettes as extra-CNS tissues that tested positive (left lung and right lung, respectively).
Case #5
On July 15, 2012, an 8-year-old male from South Carolina was admitted to hospital 2 days 
after illness onset with presumptive meningitis and started on ceftriaxone and vancomycin. 
A head CT scan on July 16 showed diffuse subarachnoid hemorrhage within the basilar 
cisterns and layering along the tentorium with accompanying left parietal soft tissue 
swelling. The patient’s condition deteriorated requiring placement of an intracranial pressure 
(ICP) monitor. He became comatose with fixed, dilated pupils and was pronounced dead on 
July 17. He was not an organ donor.
A post-mortem diagnosis of PAM was made based on testing at CDC, including wet-mount 
observation of amebae in the CSF and positive CSF PCR and cultures. The patient 
underwent an expanded autopsy and tested positive for N. fowleri in extra-CNS tissues by 
PCR. As with Cases #1 and #4, histopathology results were difficult to interpret because 
autopsy tissues were potentially cross-contaminated when CNS and extra-CNS tissue 
specimens were preserved in the same formalin container. However, in this case, organs of 
the chest and abdomen were completely dissected and fresh unpreserved tissue specimens 
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from these organs were collected and stored before the cranium was opened. These 
unpreserved tissues, collected before cross-contamination could occur, were sent to CDC for 
PCR. The brain, right lung, spleen, and intestine tested positive for N. fowleri by PCR while 
the kidney, heart, pancreas, and liver tested negative. Whether these positive PCR findings 
represented viable intact organisms in extra-CNS tissues or leakage of Naegleria debris 
across a compromised blood-brain barrier is unknown, but neither scenario could be ruled 
out. Further, it is unknown whether such leakage across the blood-brain barrier occurred pre-
mortem or post-mortem.
Case #6
On August 4, 2012, a 9-year-old male from Minnesota was admitted to hospital 2 days after 
illness onset with apparent meningitis and started on ceftriaxone, vancomycin, acyclovir, 
dexamethasone, and mannitol. An unenhanced head CT on August 5 was unremarkable. The 
patient had progressive neurologic decline requiring intubation and ICP monitor placement. 
A presumptive pre-mortem diagnosis of PAM was made based on air dried Wright-stained 
CSF cytospin preparations. The patient was pronounced brain dead on August 6. He was not 
an organ donor.
An expanded autopsy was performed on August 7. The extra-CNS organs were removed and 
specimens were prepared for PCR testing at CDC before the cranium was opened, thereby 
ruling out possible cross-contamination from the CNS. The extra-CNS organs were grossly 
and microscopically normal. Intra-parenchymal tissues were sampled by avoiding organ 
surfaces, such as the pleura and liver capsule, and by using a visibly clean scalpel for tissue 
sectioning. The organ surfaces were not cauterized before sectioning and sterile scalpels and 
forceps were not used for handling tissue samples. CSF and olfactory and auditory nerve 
tissue tested positive for N. fowleri at CDC by PCR and culture, although serum antibody 
tests were negative at 1:2. Tissue specimens from the liver, heart, kidney, and pancreas 
tested negative for N. fowleri by PCR and culture. While lung tissue was also culture 
negative, it was reproducibly PCR positive. As with Case #5, it is unknown whether this 
PCR finding represented viable intact organisms or amebic debris in the lung. Further, it is 
unknown whether such leakage across the blood-brain barrier occurred pre-mortem or post-
mortem.
Discussion
During 1995–2012, five known PAM patients in the US donated solid organs to 21 
transplant recipients; three of the cases are described above (Cases #1, #2, #3) and two more 
have been described previously (6,7). None of these recipients are known to have developed 
PAM. Further, five recipients had negative N. fowleri serologies 7 weeks to 2 years post-
transplant and one biopsy taken 1 month post-transplant from a donated heart tested negative 
for N. fowleri. However, there are data from human PAM cases and animal studies that 
challenge the assumption that N. fowleri is confined to the CNS. Since 2009, CDC has 
examined extra-CNS tissues from five PAM patients (Cases #1, 2, 4–6) and found evidence 
of varying strength to suggest extra-CNS dissemination of Naegleria might have occurred in 
four (Cases #1, 4–6) of the five cases.
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In addition to these four cases, two PAM patients with possible extra-CNS dissimenation of 
Naegleria have been previously reported. In 1943, an emaciated 22-year-old Japanese 
prisoner of war was treated pre-mortem for malaria and dysentery. On autopsy, amebae were 
observed by histology in his brain, lungs, stomach, small intestine, caecum, and mesenteric 
and gastric lymph nodes (1,15–17). In 1969, a 15-year-old female was diagnosed with PAM 
pre-mortem based motile amebae observed in her CSF (18,19). She received anti-amebic 
chemotherapy but developed acute diffuse myocarditis and pulmonary edema and died 5 
days after symptom onset. On autopsy, tissues from multiple organs were obtained under 
aseptic conditions and cultured. Spleen, liver, and lung cultures were positive for N. fowleri, 
and an ameba was observed in the heart blood.
Extra-CNS dissemination of Naegleria has also been observed in multiple experiments 
involving mice (20–24). For example, histological examinations of mice given intranasal 
Naegleria inoculations demonstrated amebae invading the nasal mucosa by 36 hours post-
inoculation, the olfactory nerve and anterior olfactory lobes by 72 hours, the cerebral 
hemispheres by 96 hours, and the lungs, liver, spleen, and renal capillaries by 108 hours (4.5 
days)with death by 132 hours in most mice (20). In a similar experiment, occasional amebae 
were histologically observed in blood vessels in and around the olfactory bulbs and within 
the bone marrow and venous sinusoids of mice skulls at 96 hours after intranasal inoculation 
(21). At the same time, amebae were also cultured from blood and lung tissue. The 
researchers noted that Naegleria entered the blood stream of the CNS and bone marrow very 
late in the disease when tissue destruction was advanced, thin-walled veins were 
compromised, and mice were moribund.
Taken together, human and animal data suggest that hematogenous spread of N. fowleri to 
extra-CNS organs might be possible. The infectious dose of N. fowleri has not been 
established in humans but may be low; in one mouse experiment, the LD50 was 300 amebae 
but the lowest intranasal lethal dose was only 39 amebae (20). Although the infectious dose 
via solid organ transplantation is unknown, these data suggest a relatively few viable 
amebae may need to escape the CNS and contaminate a organ for transplant transmission to 
be possible. Experimental data from mouse models indicated that Naegleria escape the CNS 
late in the course of disease when tissue destruction is greatest and the blood-brain barrier is 
compromised. Therefore, although no cases of donor-derived organ transplant transmission 
of N. fowleri have been reported so far, the risk of such an occurrence is likely not zero.
Since 2009, solid organ transplant transmission of Balamuthia, a related free-living ameba 
(FLA), has been reported on three occasions (9–11). It is not fully understood why 
transplant transmission of Balamuthia has been documented but not that of Naegleria to 
date. One theory has been a difference temperature sensitivities. Unlike Balamuthia, 
Naegleria are known to be thermophilic (1). However, although N. fowleri trophozoites 
degenerate within hours at temperatures <10°C, the trophozoites encyst under adverse 
conditions and cysts capable of reforming viable trophozoites under more favorable 
conditions can survive for days to months at temperatures used for organ storage and 
transportation (25). Therefore, temperature sensitivities may not explain the difference in 
transplant transmission incidence between the two organisms. Another theory is that amebic 
transplant transmission may relate to length of infection in the donor, as implied by the 
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animal experiments previously described. Unlike Naegleria, Balamuthia causes a chronic 
infection and hence has the opportunity to hematogenously spread to other organs. Also 
unlike Naegleria, Balamuthia is known to spread hematogenously from extra-CNS sites to 
the CNS (26). Moreover, the recent clusters of transplant transmission confirm that 
hematogenous spread of Balamuthia occurs from the CNS to other organs as well. However, 
the data summarized in this report suggest that hematogenous spread from the CNS to other 
organs might also occur with Naegleria. Further exploration of the risk for hematogenous 
spread of Naegleria is required to better understand the risk and risk factors for such extra-
CNS dissemination. Additionally, greater awareness of PAM among healthcare 
professionals involved in transplantation and inclusion of PAM in differential diagnoses 
during evaluations of potential donors with meningoencephalitis are needed. According to 
CDC surveillance data, only 25% of US PAM cases received a pre-mortem PAM diagnosis. 
Therefore, most PAM donors will be undiagnosed at the time of transplant.
To further define the risk of N. fowleri extra-CNS dissemination, full autopsies should be 
performed on PAM patients and any potential organ donor who dies with clinical signs or 
symptoms suggestive of meningitis or encephalitis. This practice would also help assess the 
risk of extra-CNS dissemination of other encephalitis-causing pathogens known to be 
transplant-transmitted, such as Balamuthia mandrillaris, rabies, and lymphocytic 
choriomeningitis virus (LCMV) (9–11,24,27). Full autopsies should include microscopic 
examinations of both CNS and extra-CNS tissues, particularly heart, lungs, liver, and 
kidneys. To minimize cross-contamination between CNS and extra-CNS tissues, 
examination and sampling of extra-CNS tissues and organs should be completed before 
removal of the brain. Ideally, separate workspaces and dissecting tools should be used to 
obtain CNS and extra-CNS tissues. Additionally, CNS and extra-CNS tissues should be 
placed in separate formalin containers and processed separately for paraffin embedding.
For guidance in recognizing CNS infections in potential deceased organ donors and for 
considerations during donor evaluation and organ offers, the Organ Procurement and 
Transplantation Network has provided information on their website at http://
optn.transplant.hrsa.gov/ContentDocuments/
Guidance_DTAC_CNS_Infections_07-2012.pdf (28). For assistance in diagnosing PAM, 
recommendations for N. fowleri-specific chemotherapy, and questions regarding transplant 
transmission of infectious diseases, CDC is available 24/7 by contacting the CDC 
Emergency Operations Center at 770-488-7100. Additionally, more information about the 
clinical features of PAM and its basic work-up is available on the CDC website at http://
www.cdc.gov/parasites/naegleria/health_professionals.html.
At present, no test is feasible for screening potential organ donors, no test has been approved 
for diagnostic use to detect organ recipient exposure or infection, no prophylactic 
chemotherapeutic regimen has been established, and no effective treatment regimen has 
been identified for amebic encephalitis (6). Although to date there is no evidence of 
Naegleria transplant transmission, the risk of transplantation with an organ possibly 
harboring N. fowleri, or other non-treatable agents of infectious encephalitis, should be 
carefully weighed for each individual recipient against the risk of delaying transplantation 
while waiting for another suitable organ.
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Figure 1. Post-mortem examination of lung, thyroid, heart, and spleen tissue from a 10-year-old 
male organ donor in Florida (Case #1) who died from primary amebic meningoencephalitis due 
to Naegleria fowleri in 2009
Naegleria fowleri trophozoites in lung (upper left) and thyroid (upper right) sections by 
hematoxylin and eosin (H&E) staining at 1000X magnification. Naegleria fowleri 
trophozoites fluorescing in heart (lower left) and spleen (lower right) sections by indirect 
immunofluorescence (IIF) at 200X magnification.
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Table 1
Epidemiologic and clinical summary of central nervous system disease caused by the free-living amebae 
Naegleria fowleri and Balamuthia mandrillaris in the United States1,2
Naegleria fowleri Balamuthia mandrillaris
Disease Primary amebic meningoencephalitis (PAM) Granulomatous amebic encephalitis (GAE)
Number of reported cases 
(years)
128 (1962–2012) 85 (1974–2012)
Age All ages but predominantly children (median 11 
years, range 8 months–66 years)
All ages (median 35 years, range 8 months–89 years)
Sex Males >75% of reported cases Males >65% of reported cases
Ethnicity No pattern discerned More common among Hispanics
Immune status Immunocompetent Sometimes immunosuppressed
Exposure Warm fresh water (recreational, potable) Soil and dust, possibly fresh water
Geographic distribution Historically southern-tier states but changing 
distribution to include northern states (Minnesota)
Across the United States
Seasonality Summer with peak in July and August (range April–
October)
Not apparent
Route of entry Entry through the nose during recreational water 
activities or nasal irrigation with direct spread to 
brain through cribriform plate and olfactory tract
Entry through soil contamination of skin wounds or 
cuts or through inhalation of dust with hematogenous 
spread to the brain
Incubation period Median 5 days (range 1–7 days) Unknown—believed to be weeks or months; may be 
more rapid in transplant-transmission cases
Signs and symptoms Acute onset of headache, fever, nausea, vomiting, 
stiff neck, seizures, altered mental status, 
hallucinations, coma
Subacute or chronic onset of headache, stiff neck, neck 
pain, photophobia, nausea, vomiting, altered mental 
status, behavioral changes, seizures, ataxia, focal 
neurologic deficits, impaired speech, weight loss; CNS 
symptoms may be preceded by one or more chronic 
skin lesions on face, trunk, or limbs appearing as 
nodules, ulcers, or abscesses
Differential diagnosis Bacterial or viral meningitis Brain tumor, lymphoma, stroke, vasculitis, abscess, TB 
or fungal meningoencephalitis, neurocysticercosis, 
toxoplasmosis, acute disseminated encephalomyelitis
Cerebrospinal fluid (CSF) 
parameters
Elevated opening pressure, polymophonuclear 
pleocytosis, normal or low glucose, elevated protein. 
Blood and/or motile amebae are suggestive of PAM
Normal or mildly elevated opening pressure, moderate 
lymphocytic pleocytosis, normal or low glucose, 
normal or elevated protein. Generally none to a few red 
blood cells. Amebae rarely observed
Brain imaging results3 CT and MRI often normal early in disease, then may 
show cerebral edema with basilar meningeal 
enhancement and obliteration of basilar cisterns; 
MRI might show one or more small enhancing 
round lesions in some cases 4–6
CT may show single or multiple hypodense, ring-
enhancing, space-occupying lesions with occasional 
hemorrhage within lesions; MRI similar to CT but 
might be abnormal when CT is unremarkable 4,5
Laboratory confirmation7 Amebae may be detected in CSF or tissue 
specimens
• Direct visualization of amebae with 
Giemsa-Wright or modified trichrome 
stains
• Polymerase chain reaction (PCR) testing 
for nucleic acid
• Immunohistochemistry to detect 
antigens
Serology for N. fowleri is currently considered a 
research technique and has not been evaluated for 
use as a routine diagnostic procedure.
Amebae may be detected in tissue specimens
• Direct visualization of amebae with 
hematoxylin and eosin (H&E) or periodic 
acid-Schiff (PAS) stains
• Polymerase chain reaction (PCR) testing 
for nucleic acid
• Immunohistochemistry to detect antigens
Serology for B. mandrillaris is currently considered a 
research technique and has not been evaluated for use 
as a routine diagnostic procedure.
Am J Transplant. Author manuscript; available in PMC 2015 December 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Roy et al. Page 14
Naegleria fowleri Balamuthia mandrillaris
Prognosis Mortality >99% Mortality >90%
Duration of illness from 
onset to death
Median 5 days (range 1–12 days) Median 28 days (range 4–450 days
Treatment8 No effective treatment has been established; 
multiple medications used in combination
No effective treatment has been established; multiple 
medications used in combination
Organ donors and outcomes During 1995–2012, five known PAM patients in the 
US donated solid organs to 21 transplant recipients, 
none of whom are known to have developed PAM. 
Further, five recipients had negative N. fowleri 
serologies and one biopsy from a donated heart 
tested negative for N. fowleri.
During 2009–2012, three known patients with 
granulomatous amebic encephalitis (GAE) due to 
Balamuthia in the US donated solid organs to 13 
transplant recipients: four developed GAE and died, 
one developed GAE and survived with treatment, and 
six of the remaining eight recipients who did not 
develop Balamuthia GAE developed positive 
Balamuthia serologies.9
1
Data summarized from information available on the Centers for Disease Control and Prevention (CDC) website at http://www.cdc.gov/parasites/
naegleria/index.html and http://www.cdc.gov/parasites/balamuthia/. Case counts and other epidemiologic data include unpublished data from the 
Centers for Disease Control and Prevention (CDC).
2
Roy S, Cope J, Yoder J, Visvesvara G. Free Living Ameba—What Every Clinician Needs to Know. Decision Support in Medicine [Internet]. 
2013 June [cited 2013 July10]:[about 9 pp.]. Available from https://www.decisionsupportinmedicine.com/DSM/a/articles/5/A/5523.
3CT = computed tomography; MRI = magnetic resonance imaging.
4
Kidney DD, Kim SH. CNS infections with free-living amebas: neuroimaging findings. Am J Roentgenol 1998;171:809–812.
5Singh P, Kochhar R, Vashishta RK, Khandelwal N, Prabhakar S, Mohindra S, Singhi P. Amebic meningoencephalitis: spectrum of imaging 
findings. Am J Neuroradiol 2006;27:1217–1221.
6
Rai R, Singh DK, Srivastava AK, Bhargava A. Primary amebic meningoencephalitis. Indian Pediatr 2008;45:1004–1005.
7
Diagnostic testing is not widely available for PAM. Clinicians who suspect PAM should contact their state health department and/or the CDC 
(24/7 Emergency Operation Center—770-488-1700). CDC can assist with diagnosis and provide treatment recommendations. Telediagnosis can be 
arranged at CDC by emailing photos through DPDx, CDC’s Division of Parasitic Diseases and Malaria telediagnosis tool. Instructions for 
submitting photos through DPDx are available at http://www.dpd.cdc.gov/dpdx/HTML/Contactus.htm.
8
Detailed discussions of possible chemotherapeutic drug combinations can be found at http://www.cdc.gov/parasites/naegleria/treatment-hcp.html 
and http://www.cdc.gov/parasites/balamuthia/treatment.html. For 24/7 treatment recommendations, please contact the CDC Emergency Operation 
Center at 770-488-1700.
9Gupte AA, Hocevar SN, Lea AS, Kulkarni RD, Schain DC, Casey MJ, Zendejas-Ruiz IR, Chung WK, Mbaeyi C, Roy SL, Visvesvara GS, da 
Silva AJ, Tallag J, Eckhoff D, Baddley JW. Transmission of Balamuthia mandrillaris through solid organ transplantation: utility of organ recipient 
serology to guide clinical management. [submitted to the American Journal of Transplantation].
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